Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis

37Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background. Patients with bone metastasis of gastric cancer occasionally experience disseminated intravascular coagulation (DIC), with a very poor prognosis. Methods. We treated 18 gastric cancer patients with hone metastasis with sequential methotrexate and 5-fluorouracil (sequential MTX/5-FU therapy). The treatment schedule comprised weekly administration of methotrexate (MTX; 100mg/m2, i.v. bolus) followed by 5-fluorouracil (5-FU; 600mg/m2, i.v. bolus) after an interval of 3h. Calcium leucovorin (10mg/m2, p.o. or i.v.) was administered six times, every 6h starting 24h after the administration of MTX. Results. In 11 patients with measurable metastatic lesions, the response rate was 64% (7/11). Nine patients (50%) had DIC before the initiation of chemotherapy, and 8 of them (89%) recovered from it. Two of these 9 patients (22%) survived for more than 1 year. The median survival times for all patients and for the 9 with DIC were 186 and 113 days, respectively. Grade 4 leukopenia was observed in 3 patients (17%). No treatment-related deaths occurred. Conclusion. Sequential MTX/5-FU therapy may have tive potential and may be a feasible treatment for gastric pallia-cancer patients with bone metastasis with or without DIC.

Cite

CITATION STYLE

APA

Hironaka, S. I., Boku, N., Ohtsu, A., Nagashima, F., Sano, Y., Muto, M., … Yoshida, S. (2000). Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis. Gastric Cancer, 3(1), 19–23. https://doi.org/10.1007/PL00011684

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free